Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    iberdomide | Multiple Myeloma

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04392037
Recruitment Status : Recruiting
First Posted : May 18, 2020
Last Update Posted : February 21, 2021
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
WCJ van de Donk, VU University Medical Center

Brief Summary:
Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone Phase 2

Detailed Description:

Novel drugs such as lenalidomide (an immunomodulatory drug; IMiD) have markedly improved the prognosis of multiple myeloma patients. Over the recent years, lenalidomide is increasingly used as part of first line therapy, typically until the development of progressive disease. These lenalidomide-refractory patients can be treated with several regimens. However, these regimens frequently contain proteasome inhibitors which are associated with neuropathy (bortezomib) or cardiovascular complications (carfilzomib). These proteasome inhibitors also need to be administered subcutaneously or intravenously in the hospital, once or twice per week. Also these regimens have limited efficacy in lenalidomide-refractory patients. This indicates that there is still an unmet medical need for new treatment options for patients who develop lenalidomide-refractory disease. These new treatment regimens should be active and safe without induction of neuropathy or cardiovascular side effects Moreover, an all oral regimen is frequently preferred by patients.

Iberdomide plus low-dose cyclophosphamide and dexamethasone

Available data indicates that the Cereblon E3 ligase modifying drug (CELMoD) iberdomide (CC220) is pharmacologically distinct from lenalidomide and pomalidomide with a higher potency against Cereblon, leading to differentiated antitumor and immunostimulating effects. Since iberdomide plus dexamethasone is active and well-tolerated in heavily pretreated patients including those with lenalidomide/pomalidomide-refractory disease, this two-drug regimen forms a new platform to which other agents can be added. The combinations of bortezomib, carfilzomib, or daratumumab plus iberdomide and dexamethasone are currently being evaluated.

Investigators have shown that low-dose cyclophosphamide can be effectively combined with the IMiDs lenalidomide and pomalidomide. These combinations are effective and are well-tolerated.

To address the unmet medical need for new treatment options for lenalidomide-refractory MM patients, the investigators aim at further improving the efficacy of IMiD/CELMoD plus dexamethasone combination therapy in terms of response and progression-free survival, by adding low-dose cyclophosphamide to the iberdomide-dexamethasone backbone (IberCd). This all-oral regimen will be tested in a lenalidomide-refractory patient population with 2-4 prior lines of therapy. The goal of this trial is to investigate the efficacy and safety of the IberCd combination in multiple myeloma patients who have refractory disease or a relapse after prior treatment with lenalidomide. Besides, various correlative studies will be performed during this trial including immune monitoring.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Patients will be treated with iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
Actual Study Start Date : February 17, 2021
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2023


Arm Intervention/treatment
Experimental: Iberdomide plus low-dose cyclophosphamide and dexamethasone

Iberdomide 1.6mg on days 1-21

Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle

Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone
Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
Other Name: CC-220




Primary Outcome Measures :
  1. Progression free survival [ Time Frame: up to 5 years ]
    PFS; i.e. time from the first dose of iberdomide-cyclophosphamide-dexamethasone to progression or death from any cause, whichever comes first


Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: up to 5 years ]
    In this analysis the investigators will consider the best response obtained during treatment according to the international myeloma working group (IMWG) criteria

  2. Safety and toxicity [ Time Frame: up to 5 years ]
    defined by type, frequency and severity of adverse events as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

  3. Overall survival [ Time Frame: up to 5 years ]
    measured from first dose of iberdomide-cyclophosphamide-dexamethasone, to time of death from any cause. Patients still alive or lost to follow up are censored at the date they were last known to be alive.

  4. Time to response [ Time Frame: up to 5 years ]
    defined as time from first dose of iberdomide-cyclophosphamide-dexamethasone to the first objective documentation of PR or better.

  5. Duration of response [ Time Frame: up to 5 years ]
    defined as time from documentation of tumor response to disease progression.

  6. Time to second objective disease progression (PFS2) [ Time Frame: up to 5 years ]
    defined as time from first dose of iberdomide-cyclophosphamide-dexamethasone to 2nd disease progression or death from any cause.

  7. Time to next treatment (TTNT) [ Time Frame: up to 5 years ]
    defined as the date from first dose of iberdomide- cyclophosphamide-dexamethasone to first day when subject receives another myeloma treatment. Subjects who do not start new myeloma therapy are censored at the last known alive date or first dose date, whichever is later.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Subject must have documented diagnosis of multiple myeloma and have measurable disease as defined by any of the following:

    • Serum monoclonal paraprotein (M-protein) level ≥5 g/L (0.5 g/dL); or urine M-protein level ≥200 mg/24 hours; or serum immunoglobulin free light chain ≥100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa lambda free light chain ratio (See Appendix A)

  3. Relapsed or refractory disease. Relapse is defined as progression of disease after an initial response to previous treatment, more than 60 days after cessation of treatment. Refractory disease is defined as <50% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment.
  4. Subject had 2-4 prior anti-myeloma regimens. (Note: Induction, bone marrow transplant with or without maintenance therapy is considered one regimen; Prior pomalidomide is allowed )
  5. Subject has developed lenalidomide-refractory disease (any dose) during prior treatment with lenalidomide or a lenalidomide-containing regimen Lenalidomide-refractory MM is defined as progressive disease during therapy, no response (< PR) to prior lenalidomide-containing therapy, or progression within 60 days of discontinuation from lenalidomide-containing regimens, according to the International Myeloma Working Group criteria.
  6. WHO performance 0, 1, or 2
  7. Life expectancy at least 3 months
  8. Written informed consent
  9. A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) and must:

    1. Have two negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
    2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment (including dose interruptions), and for at least 28 days after the last dose of CC-220, 90 days after the last dose of cyclophosphamide, whichever is longer. Contraception requirements are detailed in Appendix H.
  10. Male subjects must:

    a. Practice true abstinence* (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 90 days following the last dose of study treatment, even if he has undergone a successful vasectomy.

    * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.]

  11. Males must agree to refrain from donating sperm while on study treatment, during dose interruptions and for at least 90 days following last dose of study treatment.
  12. All subjects must agree to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of study treatment.
  13. All male and female subjects must follow all requirements defined in the Pregnancy Prevention Program (v5.1). See Appendix H for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.

Exclusion Criteria:

  1. Subjects who previously received continuous low-dose cyclophosphamide alone or in combination with other anti-MM agents are excluded (cyclophosphamide once weekly such as in bortezomib-cyclophospahmide-dexametahsone regimen (VCD) is allowed).
  2. Treatment with prior iberdomide
  3. Non-secretory MM
  4. Systemic AL amyloidosis or plasma cell leukemia (>2.0x109/L circulating plasma cells by standard differential) or Waldenstrom's macroglobulinemia
  5. Subject has known meningeal involvement of multiple myeloma
  6. Inadequate marrow reserve as defined by a platelet count <75 x 109/L or an absolute neutrophil count <1.0 x 109/L
  7. Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L)
  8. Subject has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide, dexamethasone, or cyclophosphamide. Subject has known or suspected hypersensitivity to the excipients contained in the formulation of iberdomide, dexamethasone, or cyclophosphamide.
  9. Subject has received any of the following within the last 14 days of initiating IberCd:

    • Plasmapheresis
    • Major surgery (as defined by the Investigator)
    • Radiation therapy other than local therapy for MM associated bone lesions
    • Use of any systemic myeloma drug therapy
  10. Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IberCd treatment
  11. Subject has current or prior use of immunosuppressive medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical or local steroid injections (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses that do not exceed 10 mg/day of prednisone or equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
  12. Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St.

    John's Wort or related products within two weeks prior to dosing and during the course of study

  13. Creatinine clearance <30 ml/min or requirement of dialysis.
  14. Uncontrolled or severe cardiovascular disease (NYHA class III or IV heart failure; myocardial infarction within the last 6 months of study entry); unstable angina; unstable cardiac arrhythmias; clinically significant pericardial disease)
  15. Significant hepatic dysfunction (total bilirubin ≥ 3 times normal value or transaminases ≥ 3 times normal value), unless related to myeloma
  16. Subject has any concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, respiratory disease, infection, hypertension, etc.) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
  17. Subject known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis A or C
  18. Peripheral neuropathy of ≥grade 2.
  19. Subjects with gastrointestinal disease that may significantly alter the absorption of CC-220
  20. History of active malignancy during the past 3 years, except squamous cell and basal cell carcinomas of the skin and carcinoma in situ of the cervix or breast and incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is cured, or malignancy that in the opinion of the local investigator, with concurrence with the principal investigator, is considered cured with minimal risk of recurrence within 3 years.
  21. Subject is known or suspected of not being able to comply with the study protocol (eg, because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  22. Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during the participation in the study
  23. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis
  24. Subject has previously received an allogeneic stem cell transplantation within 1 year before the date of registration and has not used immunosuppressive drugs within one month before the date of registration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04392037


Contacts
Layout table for location contacts
Contact: N.W.C.J van de Donk, Prof. MD PhD +31204444444 n.vandedonk@amsterdamumc.nl
Contact: C.L.B.M. Korst, MD +31204444444 c.korst@amsterdamumc.nl

Locations
Layout table for location information
Netherlands
NWZ Not yet recruiting
Alkmaar, Netherlands
Contact: M Westerman         
Amsterdam UMC, location AMC Recruiting
Amsterdam, Netherlands
Contact: J. Wegman, MD PhD         
Amsterdam UMC, location VUmc Recruiting
Amsterdam, Netherlands
Contact: N.W.C.J van de Donk, Prof. MD PhD         
Sub-Investigator: C.L.B.M. Korst, MD         
Rijnstate Recruiting
Arnhem, Netherlands
Contact: E. van der Spek, MD PhD         
Amphia Ziekenhuis Not yet recruiting
Breda, Netherlands
Contact: M Van de Klift, MD PhD         
Albert Schweitzer Ziekenhuis Recruiting
Dordrecht, Netherlands
Contact: M-D Levin, MD PhD         
UMC Groningen Not yet recruiting
Groningen, Netherlands
Contact: W. Plattel, MD PhD         
Antonius ziekenhuis Recruiting
Nieuwegein, Netherlands
Contact: O. de Weerdt, MD PhD         
Radboud UMC Not yet recruiting
Nijmegen, Netherlands
Contact: E.A. de Kort, MD         
Sponsors and Collaborators
VU University Medical Center
Celgene
Investigators
Layout table for investigator information
Principal Investigator: N.W.C.J van de Donk, Prof. MD PhD Amsterdam UMC, location VUmc
Layout table for additonal information
Responsible Party: WCJ van de Donk, Prof. Niels W.C.J. van de Donk, VU University Medical Center
ClinicalTrials.gov Identifier: NCT04392037    
Other Study ID Numbers: HAEM-2020-1
NL72835.029.20 ( Other Identifier: Toetsing Online )
2019-004604-35 ( EudraCT Number )
First Posted: May 18, 2020    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Cyclophosphamide
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents